Rachel D. Totoritis

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 475 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

DNA-Encoded Library Screening Identifies Benzo[<i>b</i>][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

Philip A. Harris, Bryan W. King, Deepak Bandyopadhyay et al. · Journal of Medicinal Chemistry · 2016 · 275 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

Philip A. Harris, Deepak Bandyopadhyay, Scott B. Berger et al. · ACS Medicinal Chemistry Letters · 2013 · 137 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis et al. · Journal of Medicinal Chemistry · 2016 · 124 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site

Mary Ann Hardwicke, Alan R. Rendina, Shawn P. Williams et al. · Nature Chemical Biology · 2014 · 108 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +10